Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)

This prospective, single-arm, open-label study aims to evaluate the real-world use of the LibAirty™ Airway Clearance System for airway clearance in adult patients with bronchiectasis in a home setting. The primary objective is to assess the rate of pulmonary exacerbations during the 12-month study period, compared to the 12 months prior to enrollment, using each participant as their own historical control.

Importantly, this study is observational in nature. Participants are prescribed the LibAirty™ system by their treating physician as part of routine clinical care, independent of study enrollment. The study does not assign participants to receive the device, nor does it provide the device as part of the study. Participants will use the LibAirty™ system in the same manner and frequency as they would outside of the study, based on the physician's clinical judgment and standard treatment protocols.

The study will observe clinical outcomes in participants who are already prescribed the device. Data will be collected prospectively during regularly scheduled clinic visits that occur as part of each participant's standard care. At up to four of these visits, information will be gathered from medical records, and participants will complete validated questionnaires to assess health-related quality of life and user satisfaction with the LibAirty™ system. Adherence to therapy will be assessed using usage logs recorded by the device.

Additional clinical outcomes such as hospitalizations, emergency department visits, use of antibiotics for exacerbations, pulmonary function test results, and healthcare resource utilization related to bronchiectasis will be monitored. No investigational procedures, treatments, or interventions are introduced or modified by the study team.

This study is designed to generate real-world evidence on the effectiveness, adherence, and patient experience associated with the LibAirty™ system when used as part of standard bronchiectasis care in the home setting.

Inclusion criteria

• Have a radiological diagnosis of Bronchiectasis based on high resolution chest CT scan
• Have bronchiectasis characterized by either:

• Daily productive cough (as determined by a treating physician)
• OR Available documentation from the last 12 months of 2 or more pulmonary exacerbations requiring antibiotic therapy
• Be at age ≥ 21 years
• Prescribed and receives the LibAirty system for home use
• Be on a standard of care treatment plan that includes at least one physician encounter every 6 months
• No change in treatment for Bronchiectasis in the 2-month period prior to enrollment
• Signed informed consent

Exclusion criteria

• Inability to independently perform therapy with the LibAirty system as directed
• Any other condition that, in the opinion of the PI, could jeopardize the safety of the subject or impact the validity of the study results.
• Pregnancy or planned pregnancy during the expected duration of the trial (12 months).